GlassScriptPhysician profile
Mona Yezdani
NPI 1831416510
$2,214.45
in general payments reported to CMS, 2019-2025
31 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $181 · 2021: $329 · 2022: $317 · 2023: $506 · 2024: $514 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,386.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $480.98 | 2023-2025 | Gemtesa, Orgovyx |
| Astellas Pharma US INC | $180.74 | 2021-2024 | Myrbetriq, Xtandi |
| Abbvie INC. | $148.74 | 2020-2025 | Botox |
| Pfizer INC. | $145.00 | 2020-2024 | |
| Teleflex LLC | $116.71 | 2021-2024 | Urolift |
| Novartis Pharmaceuticals Corporation | $109.11 | 2025 | |
| Myriad Genetic Laboratories, INC. | $100.72 | 2022-2023 | Prolaris |
| Bayer Healthcare Pharmaceuticals INC. | $82.73 | 2022-2024 | |
| Urogen Pharma, INC. | $61.88 | 2022-2024 | Jelmyto |
| Progenics Pharmaceuticals, INC. | $59.07 | 2023-2025 | Pylarify |
| Axonics, INC. | $56.73 | 2020-2023 | Axonics |
| Myovant Sciences INC. | $55.32 | 2021-2022 | |
| Amgen INC. | $54.31 | 2020-2021 | |
| Tempus Ai, INC | $54.20 | 2025 | Xt Cdx |
| Medtronic, INC. | $49.10 | 2022-2024 | Interstim |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $47.40 | 2022-2024 | Keytruda |
| Astrazeneca Pharmaceuticals LP | $45.35 | 2022 | |
| Urovant Sciences INC | $44.39 | 2021-2022 | |
| Dentsply Ih Ab | $42.88 | 2023 | Lofric |
| Accord Healthcare, INC. | $40.44 | 2022-2023 | |
| Acerus Pharmaceuticals Corporation | $37.26 | 2020-2021 | |
| Bluewind Medical | $32.88 | 2024 | Revi |
| Rochester Medical Corporation | $27.77 | 2020 | |
| Allergan, INC. | $24.50 | 2021 | |
| Procept Biorobotics Corporation | $18.91 | 2024 | Aquabeam System |
| E.R. Squibb & Sons, L.L.C. | $18.41 | 2022 | |
| Boston Scientific Corporation | $17.97 | 2022 | |
| Antares Pharma, INC. | $17.68 | 2020 | |
| Ferring Pharmaceuticals INC. | $17.39 | 2024 | Adstiladrin |
| Kowa Pharmaceuticals America, INC. | $13.91 | 2023 | Seglentis |
| Endo Pharmaceuticals INC. | $11.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mona Yezdani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.